These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21251813)

  • 21. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
    J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
    Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
    Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
    J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
    Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
    Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biweekly docetaxel-containing chemotherapy may be the optimal schedule.
    Yang X; Cai Y; Zhao X; Wang Z; Hong X; Shen Z; Ou Z; Li J; Hu X
    Anticancer Drugs; 2008 Apr; 19(4):421-6. PubMed ID: 18454052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
    Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
    Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
    Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
    Ramaswamy B; Elias AD; Kelbick NT; Dodley A; Morrow M; Hauger M; Allen J; Rhoades C; Kendra K; Chen HX; Eckhardt SG; Shapiro CL
    Clin Cancer Res; 2006 May; 12(10):3124-9. PubMed ID: 16707611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
    Jones SE; Erban J; Overmoyer B; Budd GT; Hutchins L; Lower E; Laufman L; Sundaram S; Urba WJ; Pritchard KI; Mennel R; Richards D; Olsen S; Meyers ML; Ravdin PM
    J Clin Oncol; 2005 Aug; 23(24):5542-51. PubMed ID: 16110015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel for metastatic breast cancer: two consecutive phase II trials.
    Campora E; Colloca G; Ratti R; Addamo G; Coccorullo Z; Venturino A; Guarneri D
    Anticancer Res; 2008; 28(6B):3993-5. PubMed ID: 19192662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protracted administration of weekly docetaxel in metastatic breast cancer.
    Kuroi K; Bando H; Saji S; Toi M
    Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
    Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
    J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
    Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
    Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
    Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
    Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
    J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment.
    Meier CR; Illiger HJ; Steder M; Janssen J; Deertz H; Braun M; Oeney HT; Deuss B; Küchler T; Rotermund S
    Onkologie; 2008 Sep; 31(8-9):447-53. PubMed ID: 18787352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.